Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00299780 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00299780: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00299780 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00299780, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of parathyroid hormone in combination with G-CSF when used as a stem cell mobilization regimen for patients who fail to mobilize sufficient progenitor stem cells after one or two attempts.
Interventions
- DRUG Stem cell mobilization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00299780
The ClinicalTrials.gov registry entry for NCT00299780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stem cell mobilization is the first listed.
NCT00299780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00299780 about?
NCT00299780 is a clinical study titled "Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.". The purpose of this study is to determine the safety of parathyroid hormone in combination with G-CSF when used as a stem cell mobilization regimen for patients who fail to mobilize sufficient progenitor stem cells after one or two attempts.
What is the current status of trial NCT00299780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2004-07. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00299780?
The interventions under investigation include: Stem cell mobilization (DRUG).
Who is sponsoring clinical trial NCT00299780?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.